Press Releases

Celleron Therapeutics to present CXD101 and nivolumab combination therapy Phase II clinical trial (CAROSELL) at ESMO 2019

Aug 6, 2019

Oxford, UK, 6 August 2019 – Celleron Therapeutics, the UK-based clinical stage biotech company developing personalised medicines for cancer patients,

Celleron Therapeutics Data Committee approves continuation of CXD101 and nivolumab combination therapy CAROSELL Phase II clinical trial in MSS CRC patients

Jun 17, 2019

Oxford, UK, 17 Jun 2019 – Celleron Therapeutics, a UK-based company developing personalised medicines for cancer patients, announced today approval

Celleron Therapeutics Presents at the 15th Shanghai International Colorectal Cancer Symposium (SICCS)

Jun 15, 2019

Oxford UK, 15 June 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that

Celleron Therapeutics discusses China as a Biotech Hot Spot, at BioEquity Europe 2019

May 24, 2019

Oxford, UK, 22 May 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, participated in the

Celleron Therapeutics CXD101 and nivolumab combination therapy CAROSELL clears initial Phase II clinical trial efficacy hurdle in MSS CRC patients

Apr 16, 2019

Oxford, UK, 16 April 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today the

Celleron Therapeutics announces a new cancer clinical trial of a novel immune combination therapy

Mar 21, 2019

Oxford, UK, 21 March 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announce today a

Celleron Therapeutics’ Cake Sale in Support of Comic Relief’s Red Nose Day

Mar 15, 2019

Oxford, UK, 16 March 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, held a cake

World Cancer Day: Celleron Therapeutics Commitment to Pioneering Therapies for Cancers

Feb 4, 2019

Oxford, UK, February 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, on World Cancer Day

Celleron Therapeutics announces successful completion of Phase 1b Clinical Trial

Jan 14, 2019

Celleron Therapeutics Successfully Completes Safety Evaluation of Pioneering Combination Therapy Approach to Treating Colorectal Cancer Oxford, UK, 14th January 2019

Celleron Therapeutics Announces the appointment of Simon Cook as Clinical Research Director

Jan 14, 2019

Celleron Therapeutics appoints Simon Cook as its Clinical Research Director Oxford 14 January 2019; Celleron Therapeutics Limited, the UK based